GLPG Company Profile and Key Details

Q: Who are the executives of GLPG?

Mr. Michele Manto M.B.A.Chief Commercial OfficerMs. Ellen Van Der AarHead of Devel.Dr. Andre Hoekema Ph.D.Chief Bus. Officer & Member of Management BoardMs. Elizabeth GoodwinVice President of Investor RelationsMr. Dirk De NaeyerHead of Devel. OperationsMs. Alice DietrichHead of Medical AffairsMs. Sofie Van GijselHead of Investor RelationsMs. Chantal TassetHead of Devel.Marieke VermeerschHead of Corporation CommunicationMr. Bart Filius M.B.A., MBAPres, Chief Operating Officer & Member of Management BoardDr. Walid Abi-SaabChief Medical Officer & Member of Management BoardJohn MontanaManaging Director of ArgentaDr. Walid Abi-Saab M.D.Chief Medical Officer & Member of Management BoardMr. Bart Filius MBAPres, Chief Operating Officer & Chief Financial OfficerMs. Valeria CnossenGen. CounselMs. Annelies MissottenChief HR OfficerMr. Philippe AlenSenior Vice President & Head of Bus. Devel.Mr. Thad HustonChief Financial Officer & Chief Operating Officer

NASDAQ : GLPG

Galapagos NV

$28.86

-0.3-1.03%

Open: 3:27 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Galapagos N.V. (GLPG) stock declined over -1.03%, trading at $28.86 on NASDAQ, down from the previous close of $29.16. The stock opened at $29.17, fluctuating between $28.70 and $29.20 in the recent session.

Stock Snapshot

29.16

Prev. Close

1.9B

Market Cap

28.7

Day Low

5.11

P/E Ratio

5.65

EPS (TTM)

-6.44

Cash Flow per Share

29.17

Open

65.9M

Number of Shares

29.2

Day High

74.65%

Free Float in %

42.35

Book Value

84.01K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	28.64	29.31	28.64	28.88	176.43K
Apr 13, 2026	28.16	28.56	27.98	28.56	131.8K
Apr 10, 2026	28.70	29.04	28.33	28.40	135.21K
Apr 09, 2026	28.50	28.65	28.25	28.56	112.19K
Apr 08, 2026	29.40	29.44	28.50	28.89	92.73K
Apr 07, 2026	29.00	29.00	28.27	28.93	249.52K
Apr 06, 2026	29.45	29.77	29.05	29.40	96.79K
Apr 02, 2026	29.24	29.60	29.06	29.42	175.76K
Apr 01, 2026	29.96	30.14	29.62	29.76	348.32K
Mar 31, 2026	29.00	30.46	28.98	30.00	462.72K
Mar 30, 2026	29.08	29.09	28.70	28.84	134.6K
Mar 27, 2026	29.98	30.12	28.81	28.93	371.32K
Mar 25, 2026	30.15	30.86	30.15	30.64	380.95K
Mar 24, 2026	31.26	31.40	29.68	29.80	617.41K
Mar 23, 2026	32.30	32.37	31.70	31.90	96.35K
Mar 20, 2026	32.47	32.60	31.76	32.01	134.84K
Mar 19, 2026	32.56	32.78	32.22	32.53	94.61K
Mar 18, 2026	33.12	33.12	32.17	32.17	70.52K
Mar 17, 2026	32.70	33.40	32.60	33.25	79.98K
Mar 16, 2026	32.34	32.86	32.22	32.70	64.34K

Contact Details

Mechelen, 2800

Belgium

https://www.glpg.com 321 534 2900

About Company

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.� r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Stock Peers

ARGX

19.08+2.36%

argenx SE$828.35 REGN

9.05+1.21%

Regeneron Pharmaceuticals, Inc.$755.51 UTHR

0.91+0.16%

United Therapeutics Corporation$578.54 MDGL

-0.68-0.13%

Madrigal Pharmaceuticals, Inc.$524.99 VRTX

4.23+0.96%

Vertex Pharmaceuticals Incorporated$444.28 PRAX

26.6+8.39%

Praxis Precision Medicines, Inc.$343.60 ALNY

6.41+1.92%

Alnylam Pharmaceuticals, Inc.$339.41 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.59+0.97%

Krystal Biotech, Inc.$270.00 ASND

1.29+0.52%

Ascendis Pharma A/S$249.84

Company Overview

Galapagos N.V. (NASDAQ:GLPG) closed at $28.86 USD, losing -$0.30 (-1.03%) from the previous close of $29.16. The stock is currently mid-range between its 52-week high and low $24.31 and $37.78. With a market capitalization of about $1.90 billion, Galapagos N.V. is classified as a small-cap and shows lower-than-market volatility (beta ~0.15). Key stats such as the average daily volume over the past year has been around 144.12 thousand shares, volume is running light vs its 52-week average. Headquartered in Mechelen, None, Galapagos N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Henry Gosebruch, the company employs approximately 704 people and listed since February 27, 2012. Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.

Technical Performance

GLPG has shown mixed momentum, gaining 1.12% over the past week and -2.98% over the past quarter, though year-to-date performance is up 2.39%. Short-term trend indicators are bearishly aligned (SMA20 -1.41%, SMA50 0.19%, SMA200 5.43%). The stock’s 14-day RSI is 46.41 (neutral), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.36% below its high and over 48.24% above its low. Average 10-day trading volume of 142.10 thousand shares is in line with the 3-month average of 143.92 thousand, indicating normal recent market interest.

Valuation Metrics

Galapagos N.V. trades at a P/E ratio of 5.01, slightly below the S&P 500 average, with a price-to-sales ratio of 1.45 and a price-to-book ratio of 0.5 suggesting the stock is closer to book value. The P/FCF stands at -6.05, also below market averages.

Dividend & Fair Value

Galapagos N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$22.82. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$0.55. The next quarter is forecast at -$1.15. Next year's EPS is expected at -$87.48. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $28.00. The high target offers 38.5% upside. The low target suggests -3.05% downside. The mean target is $33.25. This offers 15.13% upside. Galapagos N.V. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 103.56%. The prior quarter beat by 182.27%. Over the last six quarters, Apple has recorded several small beats. These include -187.5% in October 03, 2024.

Shareholding & Insider Activity

Galapagos N.V. has 65.90 million shares outstanding. The public float is 65.05 million shares, elevated short interest at 4.40% of float. This equals 1.85 million shares. The short ratio is 5.16 days. Institutional investors hold 30.68% of the float. Insiders own 25.35%.

Financial & Profitability Overview

Over the trailing twelve months, Galapagos NV generated $239.72M in revenue, or $3.64 per share. Gross margin was 99.99%, operating margin -53.35%, and net profit margin 88.31%. Returns are modest, with ROA at 4.86% and ROE at 7.57%.
On valuation metrics, Galapagos NV trades at a P/E of 5.01, P/S of 1.45 and P/B of 0.50. The current ratio is 20.15 and quick ratio is 20.15. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -60.60 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -20.81.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Galapagos NV posted revenue of $239.72M, down slightly from $505.28M in the prior quarter. Gross profit was $239.70M (margin 99.99%). Operating income was - $127.89M (margin -53.3%). Net income was$211.70M (EPS $3.21).
The company ended the quarter with $3.68B in cash and short-term investments, a total debt of $9.60M, and net debt of - $62.21M. Total assets were $4.36B, with equity of $2.80B. Financials further reflected weakness, with operating cash flow of - $391.21M, free cash flow of - $410.48M, and capital expenditures of - $19.27M.

Price Forecast & Outlook

Our AI price prediction model suggests that Galapagos N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.03%, with price expected at $26.85 by April 28, 2026, within a range of $26.19 to $27.54 3-Month Outlook: Projected rise of 17.8%, reaching $34.02 by July 13, 2026, with a range of $33.02 to $35.06. 1-Year Outlook: Projected loss of -4.26%, with price at $27.65 by April 14, 2027, within a range of $26.23 to $29.37.

Key Takeaways

Galapagos N.V. (NASDAQ:GLPG) shares are flat 2.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Galapagos N.V. trading at a premium to the broader market with a P/E of 5.01. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $70.79, suggesting 145.12% upside. Our AI forecast model points to short-term weakness (-7.03% over two weeks), a medium-term rise (17.8% over three months), and a longer-term loss (-4.26% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Galapagos N.V. (GLPG) stock price?

Galapagos N.V. (NASDAQ: GLPG) stock price is $28.86 in the last trading session. During the trading session, GLPG stock reached the peak price of $29.20 while $28.70 was the lowest point it dropped to. The percentage change in GLPG stock occurred in the recent session was -1.03% while the dollar amount for the price change in GLPG stock was - $0.30.

GLPG's industry and sector of operation?

The NASDAQ listed GLPG is part of Biotechnology industry that operates in the broader Healthcare sector. Galapagos N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GLPG?

Mr. Michele Manto M.B.A.
Chief Commercial Officer
Ms. Ellen Van Der Aar
Head of Devel.
Dr. Andre Hoekema Ph.D.
Chief Bus. Officer & Member of Management Board
Ms. Elizabeth Goodwin
Vice President of Investor Relations
Mr. Dirk De Naeyer
Head of Devel. Operations
Ms. Alice Dietrich
Head of Medical Affairs
Ms. Sofie Van Gijsel
Head of Investor Relations
Ms. Chantal Tasset
Head of Devel.
Marieke Vermeersch
Head of Corporation Communication
Mr. Bart Filius M.B.A., MBA
Pres, Chief Operating Officer & Member of Management Board
Dr. Walid Abi-Saab
Chief Medical Officer & Member of Management Board
John Montana
Managing Director of Argenta
Dr. Walid Abi-Saab M.D.
Chief Medical Officer & Member of Management Board
Mr. Bart Filius MBA
Pres, Chief Operating Officer & Chief Financial Officer
Ms. Valeria Cnossen
Gen. Counsel
Ms. Annelies Missotten
Chief HR Officer
Mr. Philippe Alen
Senior Vice President & Head of Bus. Devel.
Mr. Thad Huston
Chief Financial Officer & Chief Operating Officer

How GLPG did perform over past 52-week?

GLPG's closing price is 23.63% higher than its 52-week low of $24.31 where as its distance from 52-week high of $37.78 is -23.56%.

How many employees does GLPG have?

Number of GLPG employees currently stands at 704.

Link for GLPG official website?

Official Website of GLPG is: https://www.glpg.com

How do I contact GLPG?

GLPG could be contacted at phone 321 534 2900 and can also be accessed through its website. GLPG operates from Generaal De Wittelaan L11 A3, Mechelen, 2800, Belgium.

How many shares of GLPG are traded daily?

GLPG stock volume for the day was 84.01K shares. The average number of GLPG shares traded daily for last 3 months was 144.12K.

What is the market cap of GLPG currently?

The market value of GLPG currently stands at $1.90B with its latest stock price at $28.86 and 65.9M of its shares outstanding.

Employees	704
Beta	0.1
Sales or Revenue	$239.72M
5Y Sales Change%	-0.344%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GLPG Company Profile and Key Details

Galapagos NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways